Biodefense Vaccines, Vaccines for Emerging Infectious Diseases, and Coalition for Epidemic Preparedness Innovations (CEPI)

Phillip R. Pittman; Gunnstein Norheim; Benjamin Pierson; Fernando B. Guerena

doi:10.1016/B978-0-323-79058-1.00013-X

Biodefense Vaccines, Vaccines for Emerging Infectious Diseases, and Coalition for Epidemic Preparedness Innovations (CEPI)

Phillip R. Pittman, Gunnstein Norheim, Benjamin Pierson, Fernando B. Guerena

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

This chapter reviews vaccines in development for military and “For Public” emerging infectious diseases. Some of the vaccines were part of the USAMRIID Special Immunizations Program (SIP).The SIP will formally close during 2023 and final reports will be sent to the Food and Drug Administration. The SIP Program was successful at vaccinating laboratorians against certain highly infectious diseases when PPE and engineering technology were not optimal. There are no reports of occupational infectious diseases in individuals provided these vaccines in addition to the PPE in use at the time. Some believe the improvements in PPE and engineering technology over recent years have made the continued use of these 1-4 1-10 1-4 vaccines obsolete in some laboratory settings. The Coalition for Epidemic Preparedness Innovations (CEPI) is an international program that aims to develop vaccines against emerging infectious diseases across the globe. Forward looking, some of the emerging infectious diseases for which “For Public” vaccines are being developed by CEPI were part of the armamentarium of diseases for which vaccines were developed by the USAMRIID SIP program. This chapter merges discussions on vaccines developed and being developed by these programs.

Original language	English
Title of host publication	Plotkin's Vaccines, Eighth Edition
Publisher	Elsevier
Pages	172-190.e9
ISBN (Electronic)	9780323790581
ISBN (Print)	9780323790604
DOIs	https://doi.org/10.1016/B978-0-323-79058-1.00013-X
State	Published - 1 Jan 2023
Externally published	Yes

Keywords

Biodefense vaccines and other countermeasures
Coalition for Epidemic Preparedness Innovations, CEPI
Vaccines for Emerging Infectious Diseases

Access to Document

10.1016/B978-0-323-79058-1.00013-X

Cite this

@inbook{e7f85b600d164382903425a51a4d5be5,

title = "Biodefense Vaccines, Vaccines for Emerging Infectious Diseases, and Coalition for Epidemic Preparedness Innovations (CEPI)",

abstract = "This chapter reviews vaccines in development for military and “For Public” emerging infectious diseases. Some of the vaccines were part of the USAMRIID Special Immunizations Program (SIP).The SIP will formally close during 2023 and final reports will be sent to the Food and Drug Administration. The SIP Program was successful at vaccinating laboratorians against certain highly infectious diseases when PPE and engineering technology were not optimal. There are no reports of occupational infectious diseases in individuals provided these vaccines in addition to the PPE in use at the time. Some believe the improvements in PPE and engineering technology over recent years have made the continued use of these 1-4 1-10 1-4 vaccines obsolete in some laboratory settings. The Coalition for Epidemic Preparedness Innovations (CEPI) is an international program that aims to develop vaccines against emerging infectious diseases across the globe. Forward looking, some of the emerging infectious diseases for which “For Public” vaccines are being developed by CEPI were part of the armamentarium of diseases for which vaccines were developed by the USAMRIID SIP program. This chapter merges discussions on vaccines developed and being developed by these programs.",

keywords = "Biodefense vaccines and other countermeasures, Coalition for Epidemic Preparedness Innovations, CEPI, Vaccines for Emerging Infectious Diseases",

author = "Pittman, {Phillip R.} and Gunnstein Norheim and Benjamin Pierson and Guerena, {Fernando B.}",

year = "2023",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-79058-1.00013-X",

language = "English",

isbn = "9780323790604",

pages = "172--190.e9",

booktitle = "Plotkin's Vaccines, Eighth Edition",

publisher = "Elsevier",

}

TY - CHAP

T1 - Biodefense Vaccines, Vaccines for Emerging Infectious Diseases, and Coalition for Epidemic Preparedness Innovations (CEPI)

AU - Pittman, Phillip R.

AU - Norheim, Gunnstein

AU - Pierson, Benjamin

AU - Guerena, Fernando B.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - This chapter reviews vaccines in development for military and “For Public” emerging infectious diseases. Some of the vaccines were part of the USAMRIID Special Immunizations Program (SIP).The SIP will formally close during 2023 and final reports will be sent to the Food and Drug Administration. The SIP Program was successful at vaccinating laboratorians against certain highly infectious diseases when PPE and engineering technology were not optimal. There are no reports of occupational infectious diseases in individuals provided these vaccines in addition to the PPE in use at the time. Some believe the improvements in PPE and engineering technology over recent years have made the continued use of these 1-4 1-10 1-4 vaccines obsolete in some laboratory settings. The Coalition for Epidemic Preparedness Innovations (CEPI) is an international program that aims to develop vaccines against emerging infectious diseases across the globe. Forward looking, some of the emerging infectious diseases for which “For Public” vaccines are being developed by CEPI were part of the armamentarium of diseases for which vaccines were developed by the USAMRIID SIP program. This chapter merges discussions on vaccines developed and being developed by these programs.

AB - This chapter reviews vaccines in development for military and “For Public” emerging infectious diseases. Some of the vaccines were part of the USAMRIID Special Immunizations Program (SIP).The SIP will formally close during 2023 and final reports will be sent to the Food and Drug Administration. The SIP Program was successful at vaccinating laboratorians against certain highly infectious diseases when PPE and engineering technology were not optimal. There are no reports of occupational infectious diseases in individuals provided these vaccines in addition to the PPE in use at the time. Some believe the improvements in PPE and engineering technology over recent years have made the continued use of these 1-4 1-10 1-4 vaccines obsolete in some laboratory settings. The Coalition for Epidemic Preparedness Innovations (CEPI) is an international program that aims to develop vaccines against emerging infectious diseases across the globe. Forward looking, some of the emerging infectious diseases for which “For Public” vaccines are being developed by CEPI were part of the armamentarium of diseases for which vaccines were developed by the USAMRIID SIP program. This chapter merges discussions on vaccines developed and being developed by these programs.

KW - Biodefense vaccines and other countermeasures

KW - Coalition for Epidemic Preparedness Innovations, CEPI

KW - Vaccines for Emerging Infectious Diseases

UR - http://www.scopus.com/inward/record.url?scp=85211418453&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-79058-1.00013-X

DO - 10.1016/B978-0-323-79058-1.00013-X

M3 - Chapter

AN - SCOPUS:85211418453

SN - 9780323790604

SP - 172-190.e9

BT - Plotkin's Vaccines, Eighth Edition

PB - Elsevier

ER -